Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Cyclacel Pharmaceuticals, Inc. | c15823e8vk.htm |
Exhibit 99.1
|
Ernst & Young LLP George House 50 George Square Glasgow G2 1RR Tel: 0141 626 5000 Fax: 0141 626 5001 www.ey.com/uk |
| Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 |
21 April 2011 Ref: AUD/MWH/KCB |
Ladies and Gentlemen
We have read item 4.01 of Form 8-K dated April 21, 2011 of Cyclacel Pharmaceuticals, Inc. and
are in agreement with the statements contained in the first, third, fourth, fifth and seventh
paragraphs on page two therein. We have no basis to agree or disagree with other statements of
the registrant contained therein.
Regarding the registrant’s statement concerning the material weakness in internal control over
financial reporting included in the fifth paragraph on page 2 therein, we had considered such
matter in determining the nature, timing and extent of procedures performed in our audit of
the registrant’s 2009 and 2010 financial statements.
Ernst & Young LLP
